Avidity Biosciences Inc logo

RNA

Avidity Biosciences Inc

$20.6

Earnings Summary

Revenue
$1.8Mn
Net Profits
$-34.24Mn
Net Profit Margins
-1907.24%

Highlights

Revenue:

Avidity Biosciences Inc’s revenue fell -33.62% since last year same period to $1.8Mn in the Q1 2022. On a quarterly growth basis, Avidity Biosciences Inc has generated -3.08% fall in its revenue since last 3-months.

Net Profits:

Avidity Biosciences Inc’s net profit fell -43.58% since last year same period to $-34.24Mn in the Q1 2022. On a quarterly growth basis, Avidity Biosciences Inc has generated 11.17% jump in its net profits since last 3-months.

Net Profit Margins:

Avidity Biosciences Inc’s net profit margin fell -116.29% since last year same period to -1907.24% in the Q1 2022. On a quarterly growth basis, Avidity Biosciences Inc has generated 8.34% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Avidity Biosciences Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.75
EPS Estimate Current Year
-0.75

Highlights

EPS Estimate Current Quarter:

Avidity Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.75 - a 6.25% jump from last quarter’s estimates.

EPS Estimate Current Year:

Avidity Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.75.

Key Ratios

Key ratios of the Avidity Biosciences Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.71
Return on Assets (ROA)
-0.26
Return on Equity (ROE)
-0.46
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Avidity Biosciences Inc’s earning per share (EPS) fell -10.94% since last year same period to -0.71 in the Q1 2022. This indicates that the Avidity Biosciences Inc has generated -10.94% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Avidity Biosciences Inc’s return on assets (ROA) stands at -0.26.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Avidity Biosciences Inc’s return on equity (ROE) stands at -0.46.

Dividend Per Share (DPS):

Avidity Biosciences Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.8
-0.71
11.25%

Company Information

Avidity Biosciences, Inc. is driven to change lives with a new class of therapies called Antibody Oligonucleotide Conjugates (AOCs) that are designed to overcome current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity's proprietary AOC platform combines the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its other muscle programs are focused on the treatment of Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, Pompe disease and muscle atrophy. In addition to its muscle franchise, Avidity has research efforts focused on immune, cardiac and other cell types.

Organisation
Avidity Biosciences Inc
Employees
82
Industry
Health Technology